FDA grants Imbruvica broader CLL approval

FDA approved Imbruvica ibrutinib as a first-line treatment for chronic lymphocytic leukemia (CLL). AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) share U.S. rights to the drug. ...